Journal of Infectious Diseases and Medical Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Journal of Infectious Diseases and Medical Microbiology (2024) Volume 8, Issue 2

Phage therapy: An alternative to antibiotics?

David Hegarty *

Department of Colorectal, Penn University, USA

*Corresponding Author:
David Hegarty
Department of Colorectal, Penn University, USA
E-mail: dhegart3@cp.edu

Received: 26-Feb-2024, Manuscript No. AAJIDMM-24-142971; Editor assigned: 28-Feb-2024, PreQC No. AAJIDMM -24-142971 (PQ); Reviewed: 13-Mar-2024, QC No. AAJIDMM -24-142971; Revised: 15- Mar-2024, Manuscript No. AAJIDMM -24-142971 (R); Published: 20- Mar-2024, DOI:10.35841/aaagim-8.2.196

Citation: : Hegarty David. Phage therapy: An alternative to antibiotics?. J Infect Dis Med Microbiol. 2024;8(2):196.

Introduction

Phage therapy, a century-old concept, is experiencing a resurgence as the medical community grapples with the escalating problem of antibiotic resistance. Bacteriophages, or phages, are viruses that specifically infect and lyse bacteria. Discovered in the early 20th century by Frederick Twort and Félix d’Hérelle, phages were initially explored for their therapeutic potential. However, with the advent of antibiotics in the 1940s, interest in phage therapy waned. Today, as the efficacy of antibiotics diminishes and multidrug-resistant bacteria become more prevalent, phage therapy is being reconsidered as a viable alternative or complement to conventional antibiotics [1, 2].

One of the most significant advantages of phage therapy is its potential to target antibiotic-resistant bacteria. As antibiotic resistance becomes an increasingly critical global health issue, the need for alternative treatments is urgent. Phages offer a promising solution because their mode of action is entirely different from that of antibiotics. Bacteria that are resistant to antibiotics may still be susceptible to phages. Furthermore, phages can evolve alongside bacteria. When bacteria develop resistance to a particular phage, new phage variants can be selected to overcome this resistance, offering a dynamic and adaptive treatment strategy [3, 4].

Clinical applications of phage therapy have been explored in various contexts, with encouraging results. For instance, phage therapy has been used to treat chronic infections, such as those caused by Pseudomonas aeruginosa in cystic fibrosis patients, with some success. In these cases, phages have been able to penetrate biofilms – structured communities of bacteria that are notoriously difficult to eradicate with antibiotics. Phages' ability to disrupt biofilms represents a significant therapeutic advantage, as biofilm-associated infections are common in chronic wounds, medical device infections, and certain lung infections [5, 6].

Despite its potential, the application of phage therapy is not without challenges. One of the primary obstacles is the regulatory framework governing phage use. Unlike antibiotics, which are standardized chemical compounds, phages are biological entities that can vary widely. The specificity of phages means that a cocktail of different phages may be needed to effectively treat an infection, complicating the regulatory approval process. Moreover, each phage preparation must be tailored to the individual patient’s bacterial infection, which raises issues of scalability and consistency in treatment [7, 8].

Additionally, the lack of robust clinical trials poses a barrier to widespread adoption of phage therapy. While there are numerous case reports and small-scale studies demonstrating the efficacy of phages, large-scale, randomized controlled trials are necessary to establish standardized protocols and determine the safety and efficacy of phage therapy across different types of infections and patient populations. Efforts are underway to conduct such trials, and early results are promising, but more data is needed to convince regulatory bodies and the medical community of the viability of phage therapy as a mainstream treatment option [9, 10].

Conclusion

Phage therapy offers a promising alternative to traditional antibiotics, particularly in the face of rising antibiotic resistance. Its unique mode of action, specificity, and ability to evolve alongside bacteria make it a powerful tool in the fight against bacterial infections. While significant challenges remain in terms of regulation, production, and clinical validation, ongoing research and technological advancements are paving the way for phage therapy to become an integral part of modern medicine. As the medical community continues to explore and refine this approach, phage therapy has the potential to revolutionize the treatment of bacterial infections and contribute to a more sustainable future in antimicrobial therapy.

References

  1. Uyttebroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208-20.

    2. Indexed at, Google Scholar, Cross Ref

  2. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019;53(1):16-21.

    3. Indexed at, Google Scholar, Cross Ref

  3. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):10-128.

    4. Indexed at, Google Scholar, Cross Ref

  4. Usman SS, Uba AI, Christina E. Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics. Mol Biol Rep. 2023;50(8):7055-67.

    5. Indexed at, Google Scholar, Cross Ref

  5. Chegini Z, Khoshbayan A, Taati Moghadam M, et al. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Annals of clinical microbiology and antimicrobials. 2020;19:1-7.

    6. Indexed at, Google Scholar, Cross Ref

  6. Su ZT, Zenilman JM, Sfanos KS, et al. Management of chronic bacterial prostatitis. Curr Urol Rep. 2020;21:1-8.

    7. Indexed at, Google Scholar, Cross Ref

  7. Santacroce L, Di Domenico M, Montagnani M, et al. Antibiotic resistance and microbiota response. Curr Pharm Des. 2023;29(5):356-64.

    8. Indexed at, Google Scholar, Cross Ref

  8. Oromí-Bosch A, Antani JD, Turner PE. Developing phage therapy that overcomes the evolution of bacterial resistance. Annu Rev Virol. 2023;10:503-24.

    9. Indexed at, Google Scholar, Cross Ref

  9. Aranaga C, Pantoja LD, Martínez EA, et al. Phage therapy in the era of multidrug resistance in bacteria: a systematic review. Int J Mol Sci. 2022;23(9):4577.

    10. Indexed at, Google Scholar, Cross Ref

  10. Sousa C, Ferreira R, Azevedo NF, et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol. 2022;48(3):376-96.

    11. Indexed at, Google Scholar, Cross Ref

Get the App